You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 673 FIERCE-HN: a multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)

Alerts

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
673 FIERCE-HN: a multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address